

Syngene

Ref: Syn/CS/SE/BM/2021-22/July/06

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

July 20, 2021

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
--	--

Sub: Outcome of the Board Meeting

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the following:

Financial Results:

- Un-audited financial results (consolidated and standalone) as per Indian Accounting Standards (Ind-AS) for the quarter ended June 30, 2021. A copy of the un-audited financial results along with the Limited Review Reports is enclosed herewith.

The above information will also be available on the website of the Company at www.syngeneintl.com.

The Board Meeting commenced at 04:45 pm and concluded at 09:28 pm.

Kindly take the above information on record and acknowledge.

Thanking You

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Priyadarshini Mahapatra
Company Secretary and Compliance Officer

Enclosed:

- Financial results (consolidated and standalone).
- Limited Review Reports (consolidated and standalone)

SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

(Rs. in million, except per share data)

Sl. No.	Particulars	3 months ended 30 June 2021	Preceding 3 months ended 31 March 2021	Corresponding 3 months ended in the previous year 30 June 2020	Previous year ended 31 March 2021
		(Unaudited)	(Audited) (Refer note 4)	(Unaudited)	(Audited)
1	Income				
	a) Revenue from operations	5,937	6,581	4,202	21,794
	b) Other Income	123	184	153	646
	Total Income	6,060	6,765	4,355	22,440
2	Expenses				
	a) Cost of chemicals, reagents and consumables consumed	2,064	1,643	927	5,517
	b) Changes in inventories of finished goods and work-in-progress	(118)	(28)	(30)	(252)
	c) Employee benefits expense	1,679	1,773	1,365	6,415
	d) Finance costs	79	66	74	277
	e) Depreciation and amortisation expense	747	700	661	2,745
	f) Other expenses	822	1,088	665	3,585
	g) Foreign exchange fluctuation (gain)/loss, net	(154)	(47)	33	(171)
	Total expenses	5,119	5,195	3,695	18,116
3	Profit before tax and exceptional item (1-2)	941	1,570	660	4,324
4	Exceptional item [refer note 3]	-	(350)	-	(350)
5	Profit before tax (3-4)	941	1,920	660	4,674
6	Tax expense# [refer note 3]	172	315	82	637
7	Profit for the period / year (5-6)	769	1,605	578	4,037
8	Other comprehensive income				
	(A) (i) Items that will not be reclassified to profit or loss	(4)	(48)	6	(30)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1	10	(1)	5
	(B) (i) Items that will be reclassified to profit or loss	(177)	401	368	2,375
	(ii) Income tax relating to items that will be reclassified to profit or loss	26	(59)	(100)	(444)
	Other comprehensive income for the period / year, net of taxes	(154)	304	273	1,906
9	Total comprehensive income for the period / year (7+8)	615	1,909	851	5,943
10	Paid-up equity share capital (Face value of Rs.10 each)	4,008	4,000	4,000	4,000
11	Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'				24,183
12	Earnings per share (of Rs. 10 each)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	a) Basic	1.90	4.03	1.46	10.15
	b) Diluted	1.88	4.00	1.45	10.08
	# Includes credit for reversal of tax provision for earlier years amounting to Rs. 105 million for the year ended 31 March 2021.				
	See accompanying notes to the financial results				

SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021					
(Rs. in million, except per share data)					
SI. No.	Particulars	3 months ended 30 June 2021	Preceding 3 months ended 31 March 2021	Corresponding 3 months ended in the previous year 30 June 2020	Previous year ended 31 March 2021
		(Unaudited)	(Audited) (Refer note 4)	(Unaudited)	(Audited)
1	Income				
	a) Revenue from operations	5,945	6,586	4,216	21,843
	b) Other Income	123	184	153	646
	Total Income	6,068	6,770	4,369	22,489
2	Expenses				
	a) Cost of chemicals, reagents and consumables consumed	2,064	1,643	927	5,517
	b) Changes in inventories of finished goods and work-in-progress	(118)	(28)	(30)	(252)
	c) Employee benefits expense	1,711	1,826	1,404	6,602
	d) Finance costs	79	66	74	277
	e) Depreciation and amortisation expense	747	700	661	2,745
	f) Other expenses	792	1,038	637	3,429
	g) Foreign exchange fluctuation (gain)/loss, net	(154)	(47)	33	(171)
	Total expenses	5,121	5,198	3,706	18,147
3	Profit before tax and exceptional item (1-2)	947	1,572	663	4,342
4	Exceptional item [refer note 3]	-	(350)	-	(350)
5	Profit before tax (3-4)	947	1,922	663	4,692
6	Tax expense# [refer note 3]	174	316	83	643
7	Profit for the period / year (5-6)	773	1,606	580	4,049
8	Other comprehensive income				
	(A) (i) Items that will not be reclassified to profit or loss	(4)	(48)	6	(30)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1	10	(1)	5
	(B) (i) Items that will be reclassified to profit or loss	(177)	401	368	2,375
	(ii) Income tax relating to items that will be reclassified to profit or loss	26	(59)	(100)	(444)
	Other comprehensive income for the period / year, net of taxes	(154)	304	273	1,906
9	Total comprehensive income for the period / year (7+8)	619	1,910	853	5,955
10	Paid-up equity share capital (Face value of Rs.10 each)	4,008	4,000	4,000	4,000
11	Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'				24,214
12	Earnings per share (of Rs.10 each)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	a) Basic	1.91	4.04	1.47	10.18
	b) Diluted	1.89	4.01	1.46	10.11
	# Includes credit for reversal of tax provision for earlier years amounting to Rs. 105 million for the year ended 31 March 2021.				
	See accompanying notes to the financial results				

SYNGENE INTERNATIONAL LIMITED

Notes :

- 1 The statement of unaudited standalone and consolidated financial results ("the Statements") of Syngene International Limited ('the Company') for the quarter ended 30 June 2021 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 20 July 2021. The above Statements have been subjected to the limited review by the statutory auditor of the Company. The reports of the statutory auditor are unqualified. The Statements have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 The consolidated financial results include the financial results of the Company - Syngene International Limited and the financial result of the wholly owned subsidiary Syngene USA Inc. The Company and the Subsidiary are collectively referred to as 'the Group'. In addition to the above, the standalone and consolidated financial results also include the financial results in respect of Syngene Employees Welfare Trust.
- 3 Pursuant to a fire incident on 12 December 2016, certain fixed assets, inventory and other contents in one of the buildings were damaged. The Company lodged an estimate of loss with the insurance company and the survey is currently ongoing. The Company has recorded a loss of Rs. 1,057 million arising from such incident and also recognised a minimum insurance claim receivable for equivalent amounts in the respective periods till 31 March 2021. The Company has received disbursement approvals of Rs. 2,120 million from the insurance company against the loss till 31 March 2021. The aforementioned receivable and the disbursement approvals from the insurance claim has been presented on a net basis as Rs. 350 million and Rs. 713 million under Exceptional items in the financial results for year ended 31 March 2021 and 31 March 2020 respectively. Consequential tax of Rs. 122 million and Rs. 254 million is included within tax expense in standalone and consolidated financial results for the year ended 31 March 2021 and 31 March 2020 respectively.

As at 30 June 2021, the Company has receivable of Rs. Nil (31 March 2021: Rs 105) from the insurance company against the approved disbursements.

- 4 The standalone and consolidated figures for quarter ended 31 March 2021 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures upto the third quarter of the previous financial year, which were subjected to limited review.
- 5 The Group operates in a single segment of providing Contract Research and Manufacturing Services.
- 6 In March 2020, the World Health Organisation declared COVID-19 to be a pandemic. The Group has adopted measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption.

The Group has considered internal and external information while finalizing various estimates in relation to its financial statement captions upto the date of approval of the Statements by the Board of Directors. The actual impact of the global health pandemic may be different from that which has been estimated, as the COVID -19 situation evolves in India and globally. The Group will continue to closely monitor any material changes to future economic conditions.

- 7 On 27 April 2021, the Board of Directors of the Company have approved an allotment of 796,500 equity shares of Rs. 10/- (Rupees Ten each) of the Company to Syngene Employee Welfare Trust at face value pursuant to the approval at the Annual General Meeting on 24 July 2019 to allot fresh equity shares upto 1.67% of the paid-up equity capital of the Company in tranches for the purpose of implementation of the Syngene International Limited - Restricted Stock Unit Long Term Incentive Plan FY 2020.
- 8 Prior period/ year figures have been reclassified wherever required to conform to the classification of the current period/ year.

For and on behalf of the Board of Directors of
Syngene International Limited

KIRAN
MAZUMDAR
SHAW

Kiran Mazumdar Shaw
Chairperson

Digitally signed by KIRAN MAZUMDAR SHAW
DN: cn=Kiran Mazumdar Shaw, o=Syngene International Limited, email=kiran.mazumdar@syngene.com, serial=1000000000, c=IN
Date: 2021.07.20 18:14:07 +05'30'

Place :- Bangalore
Date :- 20 July 2021

B S R & Co. LLP

Chartered Accountants

KRM Tower, 1st & 2nd Floors,
No.1, Harrington Road, Chetpet,
Chennai – 600 031, India

Telephone: + 91 44 4608 3100
Fax: + 91 44 4608 3199

Limited Review Report

To
Board of Directors of Syngene International Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Syngene International Limited for the quarter ended 30 June 2021 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

B S R & Co. LLP

**Syngene International Limited
Limited Review Report (continued)**

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Co. LLP**

Chartered Accountants

Firm Registration No. - 101248W/W-100022

SIVARAMAKRISHNAN Digitally signed by
SIVARAMAKRISHNAN
AN SETHURAMAN SETHURAMAN
Date: 2021.07.20 20:08:58 +05'30'

S Sethuraman

Partner

Membership No. 203491

UDIN - 21203491AAAAED8440

Place: Chennai

Date: 20 July 2021

BSR & Co. LLP

Chartered Accountants

KRM Tower, 1st & 2nd Floors,
No.1, Harrington Road, Chetpet,
Chennai – 600 031, India

Telephone: + 91 44 4608 3100
Fax: + 91 44 4608 3199

Limited Review Report

To
Board of Directors of Syngene International Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Syngene International Limited (“the Parent”) and its subsidiary (Refer note 2 of the Statement) (the Parent and its subsidiary together referred to as “the Group”), for the quarter ended 30 June 2021 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’).
2. This Statement, which is the responsibility of the Parent’s Management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the following entities:
 - i. Syngene International Limited
 - ii. Syngene USA Inc
 - iii. Syngene Employees Welfare Trust

B S R & Co. LLP

Syngene International Limited Limited Review Report (continued)

5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Co. LLP**

Chartered Accountants

Firm Registration No. - 101248W/W-100022

**SIVARAMAKRISHNAN
AN SETHURAMAN**

Digitally signed by
SIVARAMAKRISHNAN
SETHURAMAN
Date: 2021.07.20 20:10:30 +05'30'

S Sethuraman

Partner

Membership No. 203491

UDIN - 21203491AAAAEE2185

Place: Chennai

Date: 20 July 2021